The mean change in QTc (Fridericia QT correction) for tadalafil, relative to placebo, was 3.5 milliseconds (two–sided 90% CI=1.9, 5.1). The mean change in QTc (Individual QT correction) for tadalafil, relative to placebo, was 2.8 milliseconds (two–sided 90% CI=1.2, 4.4). In this study, the mean increase in heart rate associated with a 100 mg dose of tadalafil compared to placebo was 3.1 beats per minute.Effects on Exercise Stress TestingThe effects of tadalafil on cardiac function, hemodynamics, and exercise tolerance were investigated in a single clinical pharmacology study. In this blinded crossover trial, 23 subjects with stable coronary artery disease and evidence of exercise–induced cardiac ischemia were enrolled. The primary endpoint was time to cardiac ischemia. The mean difference in total exercise time was 3 seconds (tadalafil 10 mg minus placebo), which represented no clinically meaningful difference. Further statistical analysis demonstrated that tadalafil was similar to placebo with respect to time to ischemia. Of note, in this study, in some subjects who received tadalafil followed by sublingual nitroglycerin in the post– exercise period, clinically significant reductions in blood pressure were observed, consistent with the augmentation by tadalafil of the blood–pressure–lowering effects of nitrates.Effects on VisionSingle oral doses of PDE inhibitors have demonstrated transient dose-related impairment of color discrimination (blue/green), using the Farnsworth–Munsell 100–hue test, with peak effects near the time of peak plasma levels. This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina. In a study to assess the effects of a single dose of tadalafil 40 mg on vision (N=59), no effects were observed on visual acuity, intraocular pressure, or pupillometry. Across all clinical studies with tadalafil, reports of changes in color vision were rare (less than 0.1% of patients).Effects on Sperm CharacteristicsThree studies were conducted in men to assess the potential effect on sperm characteristics of tadalafil 10 mg (one 6-month study) and 20 mg (one 6-month and one 9-month study) administered daily. There were no adverse effects on sperm morphology or sperm motility in any of the three studies. In the study of 10 mg tadalafil for 6 months and the study of 20 mg tadalafil for 9 months, results showed a decrease in mean sperm concentrations relative to placebo, although these differences were not clinically meaningful. In addition there was no adverse effect on mean concentrations of reproductive hormones, testosterone, luteinizing hormone or follicle stimulating hormone with either 10 mg or 20 mg of tadalafil compared to placebo.Dose-Response RelationshipDose-response relationships, between 20 mg and 40 mg, were not observed for 6-minute walk distance or pulmonary vascular resistance (PVR) in subjects with PAH in the placebo-controlled study. Median change from baseline in 6-minute walk distance was 32 meters and 35 meters at tadalafil 60mg uk 16 weeks in subjects receiving 20 mg and 40 mg daily, respectively. Mean change from baseline PVR was -254 dynes*sec*cm-5 and -209 dynes*sec*cm-5 at 16 weeks in patients receiving 20 mg and 40 mg daily, respectively.12.3 PharmacokineticsOver a dose range of 2.5 mg to 20 mg, tadalafil exposure (AUC) increases proportionally with dose in healthy subjects. In PAH patients administered between 20 mg and 40 mg of tadalafil, an approximately 1.5-fold greater AUC was observed indicating a less than proportional increase in exposure over the entire dose range of 2.5 mg to 40 mg.

8.7 Hepatic Impairment

In vitro data suggests that metabolites are not expected to be pharmacologically active at observed metabolite concentrations.Elimination — Following 40 mg, the mean oral clearance for tadalafil is 3.4 L/hr and the mean terminal half-life is 15 hours in healthy subjects. In patients with pulmonary hypertension not receiving concomitant bosentan, the mean oral clearance for tadalafil is 1.6 L/hr, and the mean terminal half-life is 35 hours. Tadalafil is excreted predominantly as metabolites, mainly in the feces (approximately 61% of the dose) and to a lesser extent in the urine (approximately 36% of the dose).Population pharmacokinetics — In patients with pulmonary hypertension not receiving concomitant bosentan, the average tadalafil exposure at steady-state following 40 mg was 26% higher when compared to those of healthy volunteers. The results suggest a lower clearance of tadalafil in patients with pulmonary hypertension compared to healthy volunteers.Geriatric patientsIn healthy male elderly subjects (65 years or over) after a 10 mg dose, a lower oral clearance of tadalafil, resulting in 25% higher exposure (AUC) with no effect on Cmax was observed relative to that in healthy subjects 19 to 45 years of age.Renal impairmentIn clinical pharmacology studies using single-dose tadalafil (5 mg to 10 mg), tadalafil exposure (AUC) doubled in subjects with mild (creatinine clearance 51 mL/min to 80 mL/min) or moderate (creatinine clearance 31 mL/min to 50 mL/min) renal impairment. In subjects with end-stage renal disease on hemodialysis, there was a two-fold increase in Cmax and 2.7- to 4.1-fold increase in AUC following single-dose administration of 10 mg or 20 mg tadalafil, respectively.

Tadalafil for Heart Failure

Exposure to total methylcatechol (unconjugated plus glucuronide) was 2- to 4-fold higher in subjects with renal impairment, compared to those with normal renal function. Hemodialysis (performed between 24 and 30 hours post-dose) contributed negligibly to tadalafil or metabolite elimination [see Dosage and Administration (2.2)].Hepatic impairmentIn clinical pharmacology studies, tadalafil exposure (AUC) in subjects with mild or moderate hepatic impairment (Child-Pugh Class A or B) was comparable to exposure in healthy subjects when a dose of 10 mg was administered. There are no available data for doses higher than 10 mg of tadalafil in patients with hepatic impairment. Insufficient data are available for subjects with severe hepatic impairment (Child-Pugh Class C) [see Dosage and Administration (2.3)].Patients with diabetes mellitusIn male patients with diabetes mellitus after a 10 mg sublingual tadalafil tadalafil dose, exposure (AUC) was reduced approximately 19% and Cmax was 5% lower than that observed in healthy subjects. No dose adjustment is warranted.RacePharmacokinetic studies have included subjects from different ethnic groups, and no differences in the typical exposure to tadalafil have been identified. During tadalafil 20 and 40 mg once daily dosing, steady-state plasma concentrations were attained within 5 days, and exposure was approximately 1.3-fold higher than after a single dose.Absorption — After single oral-dose administration, the maximum observed plasma concentration (Cmax) of tadalafil is achieved between 2 and 8 hours (median time of 4 hours).

Product	Dosage	Quantity + Bonus	Price
Cialis Generic	60mg	180 + 10 Pills	313.11€ 298.20€
Cialis Generic	40mg	180 + 10 Pills	277.29€ 264.09€
Tadalista Super Active	20mg	60 + 8 Pills	230.32€ 219.35€
Tadalista Super Active	20mg	90 + 10 Pills	314.14€ 299.18€
Cialis Generic	5mg	360 + 10 Pills	268.08€ 255.31€
Cialis Generic	60mg	120 + 8 Pills	240.18€ 228.74€
Cialis Generic	40mg	270 + 10 Pills	382.19€ 363.99€
Cialis Generic	40mg	10 Pills	37.79€ 35.99€
Cialis Generic	20mg	120 + 8 Pills	188.15€ 179.19€
Cialis Generic	10mg	20 Pills	48.23€ 45.93€
Tadalista Super Active	20mg	20 + 4 Pills	92.35€ 87.95€
Cialis Generic	40mg	20 Pills	59.47€ 56.64€
Cialis Generic	10mg	360 + 10 Pills	388.49€ 369.99€
Cialis Generic	20mg	10 Pills	31.49€ 29.99€
Cialis Generic	10mg	270 + 10 Pills	308.71€ 294.01€
Cialis Generic	5mg	270 + 10 Pills	205.81€ 196.01€

Absolute bioavailability of tadalafil following oral dosing has not been determined.The rate and extent of absorption of tadalafil are not influenced by food; thus tadalafil tablets may be taken with or without food.Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues. At therapeutic concentrations, 94% of tadalafil in plasma is bound to proteins.Metabolism — Tadalafil is predominantly metabolized by CYP3A to a catechol metabolite.

Storage Condition	Description	Additional Tips
Temperature	Keep below 25°C (77°F)	Avoid heat and moisture
Light Exposure	Store in a dark place	Protect from light
Container	Original packaging	Prevent moisture ingress
Shelf Life	Usually 2-3 years	Check expiration date

14.1 Tadalafil tablets for Pulmonary Arterial Hypertension

No dose adjustment is warranted.GenderIn healthy female and male subjects following single and multiple-doses of tadalafil, no clinically relevant differences in exposure (AUC and Cmax) were observed. No dose adjustment is warranted.Drug interaction studiesTadalafil is a substrate of and predominantly metabolized by CYP3A.Cytochrome P450 3A4 inhibitorsKetoconazole increased tadalafil exposure relative to the values for tadalafil alone (Figure 2). Although specific interactions have not been studied, other CYP3A inhibitors, such as erythromycin, itraconazole, and grapefruit juice, would likely increase tadalafil exposure.RitonavirRitonavir increased tadalafil 20–mg single-dose exposure relative to the values for tadalafil alone. Ritonavir inhibits and induces CYP3A, the enzyme involved in the metabolism of tadalafil, in a time-dependent manner. The initial inhibitory effect of ritonavir on CYP3A may be mitigated by a more slowly evolving induction effect so that after about 1 week of ritonavir twice daily, the exposure of tadalafil is similar in the presence of and absence of ritonavir [see Dosage and Administration (2.4) and Drug Interactions (7.5)].

The Bottom Line

Although specific interactions have not been studied, other HIV protease inhibitors would likely increase tadalafil exposure.Cytochrome P450 3A4 inducersRifampin (600 mg daily), a CYP3A inducer, reduced tadalafil 10 mg single– dose exposure (AUC) by 88% and Cmax by 46%, relative to the values for tadalafil 10 mg alone. [see Drug Interactions (7.5)].Bosentan, a substrate of CYP2C9 and CYP3A and a moderate inducer of CYP3A, CYP2C9 and possibly CYP2C19, reduced tadalafil systemic exposure following multiple-dose co-administration (Figure 2).Although specific interactions have not been studied, other CYP3A inducers, such as carbamazepine, phenytoin, and phenobarbital, would likely decrease tadalafil exposure.Exposure changes of tadalafil following co-administration with other drugs are shown in Figure 2.a Ritonavir is also a CYP2C9/CYP2C19/CYP2D6 Inhibitor and CYP3A inducer.b[see Dosage and Administration (2.4)].c Bosentan is also a CYP2C9/CYP2C19 inducer.Figure 2: Impact of Other Drugs on the Pharmacokinetics of TadalafilCytochrome P450 substrates — Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 (CYP) isoforms.Exposure changes of drugs following co-administration with tadalafil are shown in Figure 3.a A small augmentation (increase of 3 beats per minute) in heart rate was observed with theophylline.b Tadalafil (40 mg qd) had no clinically significant effect on exposure (AUC and Cmax) of bosentan metabolites.c 95% CIFigure 3: Impact of Tadalafil on the Pharmacokinetics of Other Drugs Tadalafil is an inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). The results suggest a lower clearance of tadalafil in patients with pulmonary hypertension compared to healthy volunteers.Geriatric patientsIn healthy male elderly subjects (65 years or over) after a 10 mg dose, a lower oral clearance of tadalafil, resulting in 25% higher exposure (AUC) with no effect on Cmax was observed relative to that in healthy subjects 19 to 45 years of age.Renal impairmentIn clinical pharmacology studies using single-dose tadalafil (5 mg to 10 mg), tadalafil exposure (AUC) doubled in subjects with mild (creatinine clearance 51 mL/min to 80 mL/min) or moderate (creatinine clearance 31 mL/min to 50 mL/min) renal impairment.

Tadalafil 40mg is available in some countries only as a prescription medication.
Use with caution in patients with retinal disorders or retinitis pigmentosa.
Be aware of possible side effects like dizziness, visual disturbances, or flushing.
Do not use this medication if you have recently had a stroke or heart attack.
Tadalafil 40mg can help improve quality of life for men with ED.
Always discuss your full medical history with your healthcare provider beforehand.

In subjects with end-stage renal disease on hemodialysis, there was a two-fold increase in Cmax and 2.7- to 4.1-fold increase in AUC following single-dose administration of 10 mg or 20 mg tadalafil, respectively. Exposure to total methylcatechol (unconjugated plus glucuronide) was 2- to 4-fold higher in subjects with renal impairment, compared to those with normal renal function.

Tadalafil 40mg is sometimes used off-label for other medical conditions.
Keep a record of your medication intake and any side effects.
Do not share Tadalafil 40mg with others, even if they have similar symptoms.
Tadalafil 40mg can be part of a comprehensive ED treatment plan.
Follow prescribed dosing strictly to avoid adverse effects.
Avoid driving or operating machinery if feeling dizzy after taking Tadalafil 40mg.

Hemodialysis (performed between 24 and 30 hours post-dose) contributed negligibly to tadalafil or metabolite elimination [see Dosage and Administration (2.2)].Hepatic impairmentIn clinical pharmacology studies, tadalafil exposure (AUC) in subjects with mild or moderate hepatic impairment (Child-Pugh Class A or B) was comparable to exposure in healthy subjects when a dose of 10 mg was administered. There are no available data for doses higher than 10 mg of tadalafil in patients with hepatic impairment. Insufficient data are available for subjects with severe hepatic impairment (Child-Pugh Class C) [see Dosage and Administration (2.3)].Patients with diabetes mellitusIn male patients with diabetes mellitus after a 10 mg sublingual tadalafil tadalafil dose, exposure (AUC) was reduced approximately 19% and Cmax was 5% lower than that observed in healthy subjects. No dose adjustment is warranted.RacePharmacokinetic studies have included subjects from different ethnic groups, and no differences in the typical exposure to tadalafil have been identified. No dose adjustment is warranted.GenderIn healthy female and male subjects following single and multiple-doses of tadalafil, no clinically relevant differences in exposure (AUC and Cmax) were observed. No dose adjustment is warranted.Drug interaction studiesTadalafil is a substrate of and predominantly metabolized by CYP3A.Cytochrome P450 3A4 inhibitorsKetoconazole increased tadalafil exposure relative to the values for tadalafil alone (Figure 2). Although specific interactions have not been studied, other CYP3A inhibitors, such as erythromycin, itraconazole, and grapefruit juice, would likely increase tadalafil exposure.RitonavirRitonavir increased tadalafil 20–mg single-dose exposure relative to the values for tadalafil alone. Ritonavir inhibits and induces CYP3A, the enzyme involved in the metabolism of tadalafil, in a time-dependent manner. The initial inhibitory effect of ritonavir on CYP3A may be mitigated by a more slowly evolving induction effect so that after about 1 week of ritonavir twice daily, the exposure of tadalafil is similar in the presence of and absence of ritonavir [see Dosage and Administration (2.4) and Drug Interactions (7.5)]. Although specific interactions have not been studied, other HIV protease inhibitors would likely increase tadalafil exposure.Cytochrome P450 3A4 inducersRifampin (600 mg daily), a CYP3A inducer, reduced tadalafil 10 mg single– dose exposure (AUC) by 88% and Cmax by 46%, relative to the values for tadalafil 10 mg alone.

Introduction to Tadalafil Tablets 40mg – Uses, Benefits & Global Market Demand

Across all clinical studies with tadalafil, reports of changes in color vision were rare (less than 0.1% of patients).Effects on Sperm CharacteristicsThree studies were conducted in men to assess the potential effect on sperm characteristics of tadalafil 10 mg (one 6-month study) and 20 mg (one 6-month and one 9-month study) administered daily. There were no adverse effects on sperm morphology or sperm motility in any of the three studies. In the study of 10 mg tadalafil for 6 months and the study of 20 mg tadalafil for 9 months, results showed a decrease in mean sperm concentrations relative to placebo, although these differences were not clinically meaningful. In addition there was no adverse effect on mean concentrations of reproductive hormones, testosterone, luteinizing hormone or follicle stimulating hormone with either 10 mg or 20 mg of tadalafil compared to placebo.Dose-Response RelationshipDose-response relationships, between 20 mg and 40 mg, were not observed for 6-minute walk distance or pulmonary vascular resistance (PVR) in subjects with PAH in the placebo-controlled study. Median change from baseline in 6-minute walk distance was 32 meters and 35 meters at tadalafil 60mg uk 16 weeks in subjects receiving 20 mg and 40 mg daily, respectively.

Tadalafil for Pulmonary Arterial Hypertension (PAH)

Mean change from baseline PVR was -254 dynes*sec*cm-5 and -209 dynes*sec*cm-5 at 16 weeks in patients receiving 20 mg and 40 mg daily, respectively.12.3 PharmacokineticsOver a dose range of 2.5 mg to 20 mg, tadalafil exposure (AUC) increases proportionally with dose in healthy subjects. In PAH patients administered between 20 mg and 40 mg of tadalafil, an approximately 1.5-fold greater AUC was observed indicating a less than proportional increase in exposure over the entire dose range of 2.5 mg to 40 mg. During tadalafil 20 and 40 mg once daily dosing, steady-state plasma concentrations were attained within 5 days, and exposure was approximately 1.3-fold higher than after a single dose.Absorption — After single oral-dose administration, the maximum observed plasma concentration (Cmax) of tadalafil is achieved between 2 and 8 hours (median time of 4 hours). Absolute bioavailability of tadalafil following oral dosing has not been determined.The rate and extent of absorption of tadalafil are not influenced by food; thus tadalafil tablets may be taken with or without food.Distribution — The mean apparent volume of distribution following oral administration is approximately 77 L, indicating that tadalafil is distributed into tissues. At therapeutic concentrations, 94% of tadalafil in plasma is bound to proteins.Metabolism — Tadalafil is predominantly metabolized by CYP3A to a catechol metabolite. [see Drug Interactions (7.5)].Bosentan, a substrate of CYP2C9 and CYP3A and a moderate inducer of CYP3A, CYP2C9 and possibly CYP2C19, reduced tadalafil systemic exposure following multiple-dose co-administration (Figure 2).Although specific interactions have not been studied, other CYP3A inducers, such as carbamazepine, phenytoin, and phenobarbital, would likely decrease tadalafil exposure.Exposure changes of tadalafil following co-administration with other drugs are shown in Figure 2.a Ritonavir is also a CYP2C9/CYP2C19/CYP2D6 Inhibitor and CYP3A inducer.b[see Dosage and Administration (2.4)].c Bosentan is also a CYP2C9/CYP2C19 inducer.Figure 2: Impact of Other Drugs on the Pharmacokinetics of TadalafilCytochrome P450 substrates — Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 (CYP) isoforms.Exposure changes of drugs following co-administration with tadalafil are shown in Figure 3.a A small augmentation (increase of 3 beats per minute) in heart rate was observed with theophylline.b Tadalafil (40 mg qd) had no clinically significant effect on exposure (AUC and Cmax) of bosentan metabolites.c 95% CIFigure 3: Impact of Tadalafil on the Pharmacokinetics of Other Drugs Tadalafil is an inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP).

Buy Tadalafil 40mg Tablets Online at Discounted Prices and Get FREE Shipping

2. How often do you have sex?

The mean difference in total exercise time was 3 seconds (tadalafil 10 mg minus placebo), which represented no clinically meaningful difference. Further statistical analysis demonstrated that tadalafil was similar to placebo with respect to time to ischemia. Of note, in this study, in some subjects who received tadalafil followed by sublingual nitroglycerin in the post– exercise period, clinically significant reductions in blood pressure were observed, consistent with the augmentation by tadalafil of the blood–pressure–lowering effects of nitrates.Effects on VisionSingle oral doses of PDE inhibitors have demonstrated transient dose-related impairment of color discrimination (blue/green), using the Farnsworth–Munsell 100–hue test, with peak effects near the time of peak plasma levels. This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina. In a study to assess the effects of a single dose of tadalafil 40 mg on vision (N=59), no effects were observed on visual acuity, intraocular pressure, or pupillometry.